EMEA-003474-PIP01-23 - paediatric investigation plan

ulviprubart

Key facts

• Active substance:
  ulviprubart
• Therapeutic area:
  Immunology-Rheumatology-Transplantation
• Decision number:
  P/0413/2023
• PIP number:
  EMEA-003474-PIP01-23
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of inclusion body myositis
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  25/10/2023
• Compliance check done:
  No

Decision

P/0413/2023 : EMA decision of 25 October 2023 on the granting of a product specific waiver for ulviprubart (EMEA-003474-PIP01-23)

Adopted Reference Number: EMA/469144/2023